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Abstract
Background: Constant evaluation is important for maintaining and improving the quality of end-of-life care. We
therefore conduct the fourth Japan Hospice and Palliative Evaluation Study (J-HOPE4) as a continuous evaluation study.
In this present paper, we describe the design of J-HOPE4. The main purposes of J-HOPE4 are as follows:1) to evaluate
the processes, structures, and outcomes of palliative care acute hospitals, palliative care units, and home hospice
services; 2) to examine bereaved family members’ self-reported psychosocial conditions, such as grief and depression
as bereavement outcomes;3) to provide data to ensure and improve the quality of care provided by participating
institutions via feedback based on the results from each institution; and 4) provide clinical and academic information
concerning the implications of various issues in palliative care by conducting additional studies.
Methods: We will conduct a cross-sectional, anonymous, self-reported questionnaire survey. In total, 190 institutions
will participate in this study, meaning that 12,000 bereaved family members will be sent a questionnaire.
Discussion: This is one of the largest cross-sectional surveys involving hospice and palliative care, both in Japan and
worldwide. Because this study will have a large sample size, the findings are expected to be generalizable to other
settings.
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Background
End-of-life care is an important component of cancer
care. Therefore, it is important to continuously measure
the quality of end-of-life care to maintain and improve
quality of care received by patients and their family
members [1–3].
Most studies evaluating end-of-life care have been con-
ducted with bereaved family members [4–10]. In examin-
ing end-of-life care, it can be difficult to recruit patients to
studies because terminal cancer patients are often too ill
to participate. Some researchers have developed valid
measurements to evaluate the quality of end-of-life care
from the perspective of bereaved family members such as
the Quality of Death and Dying questionnaire for end-of-
life [11], and the modified Quality of Death and Dying
questionnaire for intensive care units [9]. Therefore,
bereaved families’ survey is a useful method to evaluate
end-of-life care.
The Donabedian model, “structure, process, and out-
come,” is used as a framework for evaluating quality of
care [12]. In Japan, Morita et al. developed the Care
Evaluation Scale (CES) to evaluate the process and struc-
ture of end-of-life care [13], and Miyashita et al. devel-
oped the Good Death Inventory (GDI) to evaluate the
outcome of end-of-life care [14]. These scales have been
used as quality indicators of end-of-life care from the
perspectives of bereaved family members in Japan.
In Japan, the initial national survey for inpatient pallia-
tive care units (PCUs) was conducted in 1997. This
study developed a Satisfaction Scale for Family Members
Receiving Inpatient Palliative Care, and identified factors
contributing to satisfaction with perceived care [15]. We
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have also conducted surveys on bereaved family
members to evaluate the quality of end-of-life care from
the perspective of family members [16, 17]. As a result,
we have reported on the situation of palliative care, and
obtained new knowledge about end-of-life care. The
Japan HOspice and Palliative Evaluation (J-HOPE) Stud-
ies were conducted to evaluate hospice and palliative
care in terms of processes, structures, and outcomes
using measures such as the CES and GDI. The first J-
HOPE study was conducted between 2007 and 2008, the
second (J-HOPE2) 2010 and 2012, and the third (J-
HOPE3) between 2013 and 2014. Table 1 shows an over-
view of the previous J-HOPE studies. The first J-HOPE
study investigated 15 specific items including desirable
methods of providing information, an evaluation of care
needs, or death rattle. J-HOPE2 investigated 11 items,
including sedation, social work, and desirable nursing
care, and J-HOPE3 investigated 26 items including place
of death, end-of-life discussions, and deathbed visions.
The J-HOPE2016 was conducted as an additional survey
of J-HOPE3. These four studies reported trends and im-
portant issues in hospice and palliative care in Japan.
These previous J-HOPE studies contributed to the im-
provement of the quality of care because they revealed
the necessity points for improvement [16, 17]. Addition-
ally, feedback was provided to each participating institu-
tion so that they could compare the overall data with
their own. This helped the participating institutions to
review the strengths and weaknesses of their daily clin-
ical services.
We will conduct the fourth J-HOPE study (J-HOPE4) to
evaluate end-of-life care in Japan. In this paper, we de-
scribe the design of J-HOPE4. The main purposes of the
study are as follows: 1) to evaluate the processes, struc-
tures, and outcomes of palliative care in hospitals, PCUs,
and home hospice services; 2) to examine bereaved family
members’ self-reported psychosocial conditions, such as
grief and depression as bereavement outcomes; 3) to
provide data to ensure and improve the quality of
care provided by participating institutions via feed-
back based on the results from each institution; and
4) to provide clinical and academic information con-
cerning the implications of various issues in palliative
care by conducting additional studies.
This study has a number of strengths. First, we esti-
mate that the number of participating institutions will
be larger than those in the previous J-HOPE studies.
Second, the number of specific researches will be larger
than those in the previous J-HOPE studies. In addition,
we will combine part of the data obtained in this study
with that obtained in the East-Asian collaborative Study
to Elucidate the Dying process (EASED) in Japan
(UMIN000025457) (Fig. 1). The EASED study elucidated
the dying process and end-of-life care in terminally-ill
cancer patients admitted to PCUs before death. In the
previous three J-HOPE studies, it was difficult to explore
the causal relationship between the medical care pro-
vided before death and the quality of palliative care
because they were cross-sectional surveys. Therefore, as
part of this study, we can discuss these issues from a
longitudinal perspective. For that reason, we expect to
obtain new and valuable knowledge.
Methods
We will conduct an anonymous, cross-sectional, self-
reported questionnaire survey between May and June
2018. To identify potential subjects, we will ask each
institution to identify and list up to 80 bereaved
family members of patients who had died prior to
January 1.
Table 1 Overview of J-HOPE study
J-HOPE1 J-HOPE2 J-HOPE3
Date May–August 2007 October 2010–April 2011 May–July 2014
Participating institution 56 designated cancer centers, 100 PCUs,
14 home hospices
20 acute hospitals, 103 PCUs,
15 home hospices
20 acute hospitals, 133 PCUs, 22
home hospices
Participants 8398 completed questionnaires for analysis:
2794 responses for designated cancer
centers 5312 for PCUs
292 for home hospices
7797 completed questionnaires
for analysis: 1279 responses for
acute hospitals
5820 for PCUs
698 for home hospices
9126 completed questionnaires for
analysis: 814 responses for acute
hospitals
7294 for PCUs 1018 for home
hospices
Design Cross-sectional, anonymous, self-report
questionnaire survey
Main outcome
measurements
Care Evaluation Scale-Short Version
Good Death Inventory-Short Version
Overall Care Satisfaction
Caregiving Consequence Inventory
Care Evaluation Scale-Short Version
Good Death Inventory
Overall Care Satisfaction
Care Evaluation Scale-Short
Version
Good Death Inventory-Short
Version
Overall Care Satisfaction
Patient Health Questionnaire 9
Brief Grief Questionnaire
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The questionnaire will be sent to the bereaved family
members identified by each participating institution. A
document explaining the J-HOPE4 study’s aims and pro-
cedures will be included along with the questionnaire,
and the return of a completed questionnaire will be
considered as consent to participate in the study. A ball-
point pen will be included in the envelope as an incen-
tive to participate. Participants will be asked to return
the completed questionnaire to the secretariat office
(Tohoku University) within 2 weeks. We will send a re-
minder to nonresponders 1 month after sending the
questionnaire. If they do not wish to participate in the
study, they will be asked to check a “no participation”
box and return the incomplete questionnaire. Ethical ap-
proval for the study will be granted by the institutional
review boards of Tohoku University Hospital and all
participating institutions.
Participating institutions
We sent letters to 463 institutions which were approved
by Hospice Palliative Care Japan (HPCJ) and included 70
acute hospitals, 337 inpatient PCUs, and 56 home
hospices, and prior to July 1, 2017. Among these, 233 in-
stitutions, including 17 acute hospitals, 179 PCUs that
had not participated in the EASED study (we define
these institutions as ‘PCU-non EASED’), 21 PCUs that
had participated in the EASED study (we define these
institutions as ‘PCU-EASED’), and 16 home hospices,
are going to participate in the study.
We will ask participating institutions to describe the
treatment available, the bereavement care offered for
family members, and the structure of the patient care
provided. The structure of care in each institution in-
cludes items such as the details of religious affiliations
and the numbers of medical staff members, beds, rooms,
and patients. Considering the different care settings
(PCUs, general hospitals, and home hospice services),
we included different items to describe the institutional
structure. Items concerning available treatments, such as
surgery under general anesthesia, intravenous or oral
chemotherapy, intravenous hydration, intravenous hyper-
alimentation, pleuro- and abdominocentesis, nerve block,
physiotherapy/rehabilitation, and other complementary
and alternative medicines, were included for PCUs and
home hospices. Items concerning molecular targeted ther-
apy, hormone therapy, radiation therapy, red-blood cell
transfusion, platelet transfusion, and complementary and
alternative medicines such as Maruyama and peptide vac-
cine hypodermic injections, thermotherapy, aromatherapy,
reflexology, music therapy, lymphedema therapy by certifi-
cated specialists, and referral to available specialists, were
included for PCUs. We also reviewed the institutional in-
formation available in the HPCJ database.
Participants
The inclusion criteria are as follows: 1) the patient died
of cancer, 2) the patient was aged 20 years (the age at
which one is considered an adult in Japan) or older, and
3) the bereaved family member is aged 20 years or older.
The exclusion criteria are as follows: 1) the patient re-
ceived palliative care for less than 3 days; 2) the bereaved
family member is unavailable or cannot be identified; 3)
death was associated with treatment or occurred in an
intensive care unit; 4) the potential participant having
suffered serious psychological distress, as determined by
the primary physician and a nurse; and 5) the potential
participant is incapable of completing the self-reported
questionnaire because of health issues such as cognitive
impairment or visual disability.
Questionnaires
Two types of questionnaires will be used in this study;
main outcome (common) and specific research question-
naires. Common questionnaires will be sent to all
Fig. 1 We will connect the data obtained in the EASED study and the data that will be obtained in the J-HOPE4 study. The data obtained in
EASED study is on patient’s information before death. Therefore, we can discuss issues from a longitudinal perspective
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participants, while specific research questionnaires will
be randomly inserted into the documents sent to the
participants. Table 2 shows the structure of the ques-
tionnaires that will be sent to the participants. Common
questionnaires will include the following items and
scales. The titles of the specific research are described in
Table 3.
Overall care satisfaction
We will ask participants about their overall satisfaction
with the care the patient had received at the place of
death. The question asked is, “Overall, were you satisfied
with the medical care the patient received?” Participants
will be asked to respond using a six-point Likert scale
(1: absolutely dissatisfied, 2: dissatisfied, 3: somewhat
dissatisfied, 4: somewhat satisfied, 5: satisfied, and 6: ab-
solutely satisfied).
Care evaluation scale-short version
The CES was developed to measure end-of-life care
from the perspective of bereaved family members, with a
focus on the structure and process of care. The original
version of the CES includes 10 domains and 28 attri-
butes. The questionnaire was designed to ensure that
respondents evaluated the structure and process of end-
of-life care by rating the need for improvement for each
item on a six-point Likert scale (1: improvement is
highly necessary; 2: improvement is quite necessary; 3:
improvement is necessary; 4: improvement is somewhat
necessary; 5: improvement is slightly necessary; and 6:
improvement is not necessary). Total scores will be
transferred to a 100-point scale, with higher scores indi-
cating better care. The short version of the CES consists
of 10 representative items from each domain, and the
validity and reliability of the scale have been confirmed
[13]. We will use the revised short version of the CES
(CES2) in the current study [18].
Good death inventory-short version
We will use the short version of the GDI to measure pa-
tients’ achievement of a good death from the perspective
of bereaved family members. The original version of the
GDI consists of 10 core and 8 optional domains and 54
attributes. The 10 core domains evaluate the attributes
that Japanese people consistently rate as important, and
the 8 optional domains evaluate attributes that are rated
as important, albeit inconsistently, and depend upon in-
dividual values [14]. The short version of the GDI con-
sists of 18 representative items from each domain, and
the validity and reliability of the scale have been con-
firmed. Participants will evaluate each attribute using a
seven-point Likert scale (1: absolutely disagree, 2: dis-
agree, 3: somewhat disagree, 4: unsure, 5: somewhat
agree, 6: agree, and 7: absolutely agree). The total score
will be calculated by summing the scores for all attri-
butes, with a high total score indicating the achievement
of a good death.
Brief grief questionnaire
We will use the Brief Grief Questionnaire (BGQ) to as-
sess complicated grief (CG). The BGQ was developed by
Shear et al., and the reliability and validity of the Japa-
nese version have been confirmed [19]. Although the
BGQ was originally developed to assess CG in people
who had lost a loved one to, in the September 11 at-
tacks, Fujisawa et al. used the questionnaire with the
general Japanese population including bereaved individ-
uals who had lost a loved one to cancer [20]. A total
score of 8 or higher indicates that the respondent is
likely to develop CG, scores of 5–7 indicate subthreshold
CG, and scores of < 5 indicate that the respondent is un-
likely to develop CG.
Patient health questionnaire 9
The Patient Health Questionnaire 9 is a widely accepted
instrument that consists of 9 items used to assess de-
pressive symptoms. This instrument is widely used as a
brief diagnostic tool and measures the severity of de-
pression in both clinical practice and research; the reli-
ability and validity of the scale have been confirmed
[21–23]. Each of the nine items concerns the extent to
which a particular depressive symptom has bothered the
respondent in the preceding 2 weeks. Responses are pro-
vided on a scale ranging from 0 (not at all) to 3 (nearly
every day), and total scores range from 0 to 27. Scores of
5, 10, 15, and 20 represent valid cutoff points representing
minimal, mild, moderate, moderately severe, and severe
depression [21].
Table 2 Structure of questionnaire will be sent to subjects
Common questionnaire Specific research questionnaire Total
Number of pages 8 4 12
Included question items or scales • Care Evaluation Scale-Short Version
• Good Death Inventory-Short Version
• Overall Care Satisfaction
• Patient Health Questionnaire 9
• Brief Grief Questionnaire
• Symptoms patients perceived 1 week before death
• Participant Characteristics
Question items from two or three
specific researches selected at random
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Symptoms
We will ask the bereaved family members to report phys-
ical symptoms that the patients experienced 1 week before
death. If an eligible patient had experienced a symptom,
the bereaved family will describe the degree of symptom
severity. Responses will be provided on a scale ranging
from 0 (not at all) to 4 (very acute). The targeted symp-
toms are: 1) pain; 2) fatigue; 3) nausea; 4) constipation; 5)
anorexia; 6) weight loss; 7) drowsiness; 8) insomnia; 9)
dyspnea; and 10) itching.
Data analysis
Expected sample size
Since this research is a questionnaire survey, the expected
number of questionnaires to be sent was considered based
on accuracy. We estimate that 20 acute hospitals, 150
Table 3 List of specific studies
Title
1. The impact of socioeconomic status on the outcomes of end-of-life care and bereavement
2. The experiences of patients and their families who had cancer of an unknown primary source
3. Care burden, turnover, and death incidences in family caregivers of cancer patients
4. Association between previous experience of end-of-life-care among family caregivers and preference of place of care and death
5. Factors that contribute to good death; perspectives form bereaved families of cancer patients
6. Relatives’ perceptions about the timing of referral and administration to hospice and palliative care units
7. Differences in perception of symptoms and the association between medical staff and caregivers and recommendations about the attitudes of
medical staff
8. Non-pharmacological care preferred in the management of dyspnea for advanced cancer patients
9. Content and timing of communication between patients and their families that form the basis for end-of-life discussion; the influence on
well-understood feelings and implementation of end-of-life discussion
10. Personalized symptom goal; perspectives from the bereaved family members
11. With or without chemical coping based on the judgment of the family: experiences, knowledge, and needs of the family on chemical coping
12. Bereaved family members’ preferences for timing of consultation/referral to palliative care
13. Effects of advanced care planning on its relationship and view of life and death
14. Desirable communication between cancer patients who have difficulty communicating and their families
15. Physician’s explanations about the discontinuation of aggressive anticancer therapy from the viewpoint of behavioral economics
16. Important outcomes of pharmacotherapy for dyspnea in terminal cancer patients from the perspective of the bereaved family
17. Positive effects of bereavement on the bereaved family
18. Psychological effects among families of deceased using electrocardiograph monitor within 24 h before death
19. Diagnosis of complicated grief and medical economic assessment
20. Desirable bereavement care in hospice and palliative care unit from perspective of bereaved families
21. Family experiences with terminal cancer patients with cognitive impairment
22. Effects of rehabilitation on terminal cancer patients on quality of life, and its desirable implementation
23. Families’ perceptions and needs of intravenous nutrition and hydration among advanced cancer patients
24. Coping behavior after bereavement and use of bereavement care services, and its association with grief/depression
25. Effect of family function after bereavement on depression and grief among the bereaved family
26. Bereaved family’s perceptions of immunotherapy
27. Validity of VOICES-SF Japanese version
28. Family conflicts of patients using specialized palliative care
29. Social dysfunction and labor gains/losses caused by grief after bereavement
30. Utilization of family-care leave and barriers that impede its utilization
31. Association between social distress experienced by bereaved families and social capital
32. Meaning/importance of taking a bath among Japanese terminal cancer patients
33. Spiritual pain among family caregivers of terminal cancer patients
34. Survey on cases where the place of death was not home despite transfer of place of care to the home
35. Needs in visiting nursing care and role strain in home hospice/palliative care settings
36. Chemical coping led by the family; experiences, knowledge, and needs of the family regarding to chemical coping
37. Coping behavior after the death of a loved one and use of bereaved family care services, and its association with grief/depression
38. Accuracy of recall on the patient’s symptoms, and medical practice and explanations among bereaved family
39. Does continuous deep sedation lessen communication between patients and their families?
40. Psychological outcomes of bereaved families who experience unexpected sudden death in the palliative care units
41. Bereaved families’ experiences regarding to death rattle and aspiration
42. Association between evaluation of bereaved families regarding the treatment and care for end-of-life delirium and their depression/grief/pain
43. Validity of the Good Death Scale Japanese version
44. What are the desirable death pronouncements in palliative care units?
45. Bereaved families’ opinions about pneumonia treatment
46. What symptoms and medical practices can easily cause family conflicts?
47. Influence of discussion about do-not-attempt-resuscitation with terminal cancer patients on the psychological burdens and thoughts of
bereaved families
48. End of life experiences such as ‘Deathbed vision’ in palliative care units
49. Evaluation of sedation based on protocol by bereaved families
50. Quality of life of patients with malignant gastrointestinal obstruction at the end-of-life and influences on their families
51. Resilience of relatives of terminal cancer patients and its influence on their mental health
52. Association between events and care in the dying process of cancer patients and the mental health of bereaved families
53. Association between the use of ‘complementary and alternative medicines’ and depression or grief of bereaved families
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PCUs, and 20 home hospice services will participate in
the study because about 180 institutions participated in J-
HOPE3 and the number of institutions approved by HPCJ
has increased. If each institution identifies 80 participants,
then 12,000 participants at PCUs, 1600 at acute hospitals,
and 1600 at home hospices will be identified. Therefore,
the total number of expected participants is about 15,000.
The number of responses eligible for analysis is expected
to be about 9750 because we estimate that the response
rate will be about 65% in accordance with the previous J-
HOPE studies.
Main statistical analyses
We will calculate the mean and distribution of each out-
come measurement by institution. We will perform uni-
variable and multivariable analyses using outcome
measurements as objective variables. Therefore, we will
reveal the factors associated with outcomes such as GDI
and CES.
In terms of specific research, each principle investiga-
tor calculated sample size, and will analyze data accord-
ing to each research plan.
Discussion
This paper outlines the study protocol of J-HOPE4. The
main objective is to evaluate the processes, structures,
and outcomes of palliative care in acute hospitals, PCUs,
and home hospice services. This is one of the largest
cross-sectional surveys involving hospice and palliative
care, that has been conducted both in Japan and world-
wide. This study has several strengths and limitations.
Strengths
We think our study has several strengths. First, the sam-
ple size is large. Therefore, the findings are expected to
be generalizable to other settings. Second, because this
study includes many specific researches, we are likely to
obtain useful knowledge for clinical practice.
Limitation
The participants are those who lost a loved one in a
HOPCJ member facility in Japan. Therefore, the findings
of this study may not be generalizable to other countries.
In addition, there may be recall bias because of the
retrospective nature of the study. However, according to
some studies, considering both recall bias and grieving
process, 3–12 months after death may be an appropriate
time frame for participant inclusion [24–26].
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